HC Wainwright Has Optimistic View of CRVS FY2025 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.43) per share for the year, up from their prior estimate of ($0.44). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2027 earnings at ($0.32) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Separately, Oppenheimer reissued an “outperform” rating and issued a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Corvus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ:CRVS opened at $3.37 on Friday. The company has a 50 day moving average price of $4.64 and a two-hundred day moving average price of $6.06. The company has a market capitalization of $216.55 million, a PE ratio of -3.62 and a beta of 0.91. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtus ETF Advisers LLC bought a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $47,000. PKS Advisory Services LLC bought a new stake in shares of Corvus Pharmaceuticals in the fourth quarter valued at about $56,000. Alpine Global Management LLC acquired a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth about $62,000. ExodusPoint Capital Management LP bought a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth about $72,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $73,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.